Revance Therapeutics (RVNC) Financials

Revance Therapeutics Inc (RVNC) is a biotechnology company that specializes in the development and commercialization of novel aesthetic and therapeutic products. The company's financial performance is reflected in its income statement, which details its revenue, expenses, and net income from stockholders. In the latest reported period, Revance Therapeutics Inc generated total revenue of $22.5 million, representing a significant increase compared to the previous year. The company's gross profit was $14.3 million, indicating a healthy margin on its products and services. However, after accounting for operating expenses, the company reported an EBIT loss of $78.9 million.

Revance Therapeutics Inc's balance sheet shows a strong financial position with total assets of $604.8 million. The company has a significant amount of cash equivalents, which provide liquidity and flexibility in its operations. Additionally, Revance Therapeutics Inc has a favorable stockholders equity of $285.6 million, indicating a solid base of shareholder support. However, the company also has total debt of $223.4 million, which should be carefully managed to avoid excessive leverage.

In terms of cash flow, Revance Therapeutics Inc has been focused on financing its operations and investing in research and development initiatives. The company has a positive operating cash flow, indicating that its core business is generating cash. However, the company has been utilizing its financing cash flow to meet its capital requirements and fund its growth strategies. The investing cash flow reflects the company's investments in property, plant, and equipment, as well as acquisitions of intangible assets. Overall, Revance Therapeutics Inc strives to maintain a balanced cash flow to support its long-term growth and profitability.